Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

Review

(3057) Views  (607) Full article downloads

Authors: Gabriele Nicolini, Nicola Scichilone, Andrea Bizzi, Alberto Papi, Leonardo M Fabbri

Published Date November 2008 Volume 2008:4(5) Pages 855 - 864

DOI: http://dx.doi.org/10.2147/TCRM.S3126

Gabriele Nicolini¹, Nicola Scichilone², Andrea Bizzi³, Alberto Papi⁴, Leonardo M Fabbri⁵

¹Medical Department, Chiesi Farmaceutici, Parma, Italy; ²University of Palermo, DIMPEFINU, Palermo, Italy; ³Department of Scientific Affairs, Chiesi Farmaceutici, Parma, Italy; ⁴Research Center on Asthma and COPD, University of Ferrara, Ferrara, Italy; ⁵Section of Respiratory Diseases, University of Modena, Modena, Italy

Abstract: Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient–device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient’s perspective.

Keywords: beclomethasone, formoterol, modulite, extrafine